Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

filgotinib

JYSELECA

filgotinib (JYSELECA) is a tyrosine-protein kinase jak3 inhibitor.

EMA: approved Antineoplastic and immunomodulating agents (L04) L04AF04
Patents linked 7
Pipeline programs 18
News articles 0
Drug details — filgotinib
Class
Antineoplastic and immunomodulating agents (L04)
Route
—
Patents
7
Programs
18
Data quality
0.83
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

filgotinib (JYSELECA) is a tyrosine-protein kinase jak3 inhibitor.

Key facts

INN filgotinib
Brand JYSELECA
Mechanism Tyrosine-protein kinase JAK3 inhibitor
Target Tyrosine-protein kinase JAK1
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AF04

Mechanism of action

Tyrosine-protein kinase JAK3 inhibitor

Primary target: Tyrosine-protein kinase JAK1

Approval history

Authority Status Date
EMA approved —

Pipeline programs

Browse pipeline
  1. Filgotinib Phase 3 · Lakefront Biotherapeutics NV · Crohn's Disease
  2. Filgotinib Phase 3 · Lakefront Biotherapeutics NV · Ulcerative Colitis
  3. Filgotinib Phase 3 · Lakefront Biotherapeutics NV · Psoriatic Arthritis
  4. Filgotinib Phase 3 · Lakefront Biotherapeutics NV · Ankylosing Spondylitis
  5. Filgotinib Phase 3 · Alfasigma · Axial Spondyloarthritis
  6. GLPG0634-CL-329 Phase 3 · Alfasigma · Polyarticular-course juvenile idiopathic arthritis
  7. GLPG0634-CL-331 Phase 3 · Alfasigma · Ulcerative colitis
  8. GLPG0634-CL-333 Phase 3 · Alfasigma · Juvenile idiopathic arthritis

Related & competitor drugs

Browse all drugs
  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)

Related patents

Browse patents

  1. WO 2026027669

    BIOMARQUEURS POUR DÉTERMINER LE TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AVEC DU FILGOTINIB

    Expires Wed Jan 31 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. IT 202300012522

    FLUOROMETIL-CARNITINA PER USO COME INIBITORE DI COLINA TRIMETILAMMINA (TMA) LIASI.

    Expires Sat Dec 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. AU 2023257308

    USES OF FARNESOID X RECEPTOR AGONISTS

    Expires Wed Oct 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. CA 3263063

    VELUSETRAG DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA PSEUDO-OBSTRUCTION INTESTINALE CHRONIQUE (POIC)

    Expires Wed Mar 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. CA 3222905

    UTILISATION DE SOUCHES BACTERIENNES DE LACTOBACILLUS PARACASEI DANS LE TRAITEMENT DE NOUVEAU-NES

    Expires Wed Jan 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. EP 3986378

    PHARMAZEUTISCHE ZUSAMMENSETZUNGEN IN FORM VON GEL MIT XYLOGLUCAN UND ALKOHOLEN ZUR KONTROLLIERTEN FREISETZUNG VON WIRKSTOFFEN

    Expires Tue Apr 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. WO 2019180199

    COMPOSITION AQUEUSE STABLE DE PHOSPHOCRÉATINE

    Expires Wed Sep 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is filgotinib?

filgotinib (JYSELECA) is a tyrosine-protein kinase jak3 inhibitor.

What is the brand name for filgotinib?

JYSELECA is a marketed brand name for filgotinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.